Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
99 hedge funds and large institutions have $352M invested in Insys Therapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 39 increasing their positions, 26 reducing their positions, and 28 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 26
0% more funds holding
Funds holding: 99 → 99 (0)
0% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 28
5% less capital invested
Capital invested by funds: $372M → $352M (-$20.2M)
39% less call options, than puts
Call options by funds: $2.61M | Put options by funds: $4.25M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
+$25.9M |
| 2 |
BTP
Bloom Tree Partners
New York
|
+$25.4M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$25.1M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$12.5M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$8.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$21M |
| 2 |
TCM
Tamarack Capital Management
Carlsbad,
California
|
-$19.8M |
| 3 |
Renaissance Technologies
New York
|
-$5.68M |
| 4 |
D.E. Shaw & Co
New York
|
-$4.94M |
| 5 |
Two Sigma Investments
New York
|
-$4.02M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSG
126
Summit Securities Group
New York
| – | -$8K | -400 | Closed |
|
127
Ameriprise
Minneapolis,
Minnesota
| – | -$2.1K | -130 | -81% |
|
INSY Hedge Fund Activity: Q2 2014 in Review
99 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q2 2014, worth a combined $352M — down 5.4% from $372M a quarter earlier.
Fund positioning in INSY was balanced in Q2 2014: 28 funds opened new positions, 28 closed out, 39 added to existing stakes and 26 trimmed.
The largest buyer was Empyrean Capital Partners, opening a new position worth an estimated $25.9M. The largest seller was AllianceBernstein, cutting an estimated $21M.
- 99 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q2 2014, unchanged from Q1 2014.
- Funds reported $352M of Insys Therapeutics, Inc. stock for Q2 2014, down 5.4% quarter-over-quarter.
- 28 funds opened new Insys Therapeutics, Inc. positions in Q2 2014 and 28 closed out, a net change of 0 holders.
- The largest Insys Therapeutics, Inc. buyer in Q2 2014 was Empyrean Capital Partners, an estimated $25.9M added.
- The largest Insys Therapeutics, Inc. seller in Q2 2014 was AllianceBernstein, an estimated $21M sold.
Based on aggregated 13F filings for Q2 2014.